Weight LossNCT06843512
Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication
An observational study of Weight Loss and Food Selection, run by Penn State University at 1 site in United States.
Trial summary
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Weight Loss, Food Selection
- What is being tested?
- GLP-1 Medication Initiation
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jul 2025to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants will be identified from a list of medical patients prescribed GLP-1 medication by their physicians (located in offices near State College or Hershey, PA) and who volunteered to be contacted regarding studies they are eligible for.
Who may be able to join
- Adults (18+) with overweight or obesity (BMI >25 kg/m2)
- Not currently taking an incretin-based medication at baseline
- Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
- Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
- Fluent in English
Who cannot join
- Adults (18+) without overweight or obesity
- <18 years of age at time of testing
- Adults not taking a GLP-1 Medication
- Adults taking a compound GLP-1
- Adults on GLP-1 medication for longer than 2 weeks at baseline
- Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
- Not fluent in English
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University
State College, Pennsylvania, 16802
Christina M Blackmon, 425-499-8049, cmb8633@psu.edu
About this study
Official title: Exploring the Influence of GLP-1 Medication on Food Attitudes and Selection in a Virtual Reality Buffet
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.
- Conditions
- Weight Loss, Food Selection
- Being tested
- GLP-1 Medication Initiation
- Keywords
- GLP-1, Weight Loss, Virtual Reality, Food behavior
- Medical subject headings
- Weight Loss, Food Preferences
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GLP-1 Medication InitiationOther
One visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits.
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in Total Weight of Food Selected in the VR Buffet at 3 Months
Measured: Baseline and 3 months
Change from Baseline in Total Calories of Food Selected in the VR Buffet at 3 Months
Measured: Baseline and 3 months
Change from Baseline in Energy Density of Food Selected in the VR Buffet at 3 Months
Measured: Baseline and 3 months
Change from Baseline in Variety of Food Selected in the VR Buffet at 3 Months
Measured: Baseline and 3 months
Secondary outcomes (6)
Change in Baseline Weight Watchers Food Noise Score at 3 Months
Based on participant's answers to the WW Food Noise questionnaire; Scale of 1-5, 1 being strongly disagree and 5 being strongly agree; Higher scores mean more food noise
Measured: Baseline and 3 months
Change in Baseline 9-question External Food Cue Responsiveness Questionnaire Score at 3 Months
Answers are on a 1-4 scale with 1 being "Rarely" and 4 being "A lot"; higher scores suggest more external food cue reactivity
Measured: Baseline and 3 months
Change in Baseline Adult Eating Behavior Score at 3 Months
Answers on a 1-5 scale with 1 being "Strongly disagree" and 5 being "Strongly agree"; 8 subscales, high scores indicate greater expression of subscale measure
Measured: Baseline and 3 months
Change in Baseline Three-Factor Eating Questionnaire Score at 3 Months
Rated on a scale of 1-4 with 1 being "Definitely false" and 4 being "Definitely true"; 3 subscales, higher scales on each means greater expression of that behavior
Measured: Baseline and 3 months
Change in Baseline General Food Craving-Trait Scale Score at 3 Months
Rated on a 0-5 scale with 0 being "Never/not applicable" and 5 being "Always"; higher scores mean more food dependent
Measured: Baseline and 3 months
Change in Baseline Buffet Food Liking Scores at 3 Months
Rated on a 0-100 scale with 0 being "Dislike extremely" and 100 being "Like extremely"; high scores mean greater liking of the food
Measured: Baseline and 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Feb 2025
- Study start15 Jul 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Weight LossStudies of the same condition, open and under way.
- More trials run by Penn State UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Penn State University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Travis Masterson, Penn State University
- Investigators
- Travis Masterson, Principal investigator, The Pennsylvania State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06843512
- Sponsor's protocol ID
- STUDY00026642
- Status last verified
- Sep 2025
- First submitted
- 20 Feb 2025
- Last updated
- 10 Sep 2025
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Influence of GLP-1 Medication on Food Attitudes and Selection in a Virtual Reality Buffet
- ClinicalTrials.gov ID
- NCT06843512
- Acronym / sponsor ID
- STUDY00026642
- Conditions
- Weight Loss, Food Selection
- Keywords
- GLP-1, Weight Loss, Virtual Reality, Food behavior
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Penn State UniversityUniversity, hospital or other
- Study start
- 15 Jul 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 25 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be identified from a list of medical patients prescribed GLP-1 medication by their physicians (located in offices near State College or Hershey, PA) and who volunteered to be contacted regarding studies they are eligible for.
Key inclusion criteria (5 listed)
- Adults (18+) with overweight or obesity (BMI >25 kg/m2)
- Not currently taking an incretin-based medication at baseline
- Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia)
- Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy.
- Fluent in English
Key exclusion criteria (7 listed)
- Adults (18+) without overweight or obesity
- <18 years of age at time of testing
- Adults not taking a GLP-1 Medication
- Adults taking a compound GLP-1
- Adults on GLP-1 medication for longer than 2 weeks at baseline
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GLP-1 Medication InitiationOne visit before starting GLP-1 medication and one visit 3 months after. No other changes administered between visits. | Other | – |
Primary outcome
Change from Baseline in Total Weight of Food Selected in the VR Buffet at 3 Months
Time frame: Baseline and 3 months
Change from Baseline in Total Calories of Food Selected in the VR Buffet at 3 Months
Time frame: Baseline and 3 months
Change from Baseline in Energy Density of Food Selected in the VR Buffet at 3 Months
Time frame: Baseline and 3 months
Change from Baseline in Variety of Food Selected in the VR Buffet at 3 Months
Time frame: Baseline and 3 months
6 secondary outcomes
Change in Baseline Weight Watchers Food Noise Score at 3 Months
Time frame: Baseline and 3 months
Change in Baseline 9-question External Food Cue Responsiveness Questionnaire Score at 3 Months
Time frame: Baseline and 3 months
Change in Baseline Adult Eating Behavior Score at 3 Months
Time frame: Baseline and 3 months
Change in Baseline Three-Factor Eating Questionnaire Score at 3 Months
Time frame: Baseline and 3 months
Change in Baseline General Food Craving-Trait Scale Score at 3 Months
Time frame: Baseline and 3 months
Change in Baseline Buffet Food Liking Scores at 3 Months
Time frame: Baseline and 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Weight Loss
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
A Pilot Factorial Trial of an Integrated Lifestyle Intervention
Physical Inactivity, Overweight and Obesity
RecruitingPhase 1/2
Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia
Cancer, Cachexia
Active, not recruitingPhase 3
AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Diabetes Mellitus, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Travis Masterson principal investigator
The Pennsylvania State University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Weight Loss and Food Selection, run by Penn State University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christina M Blackmon (425-499-8049, cmb8633@psu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in Total Weight of Food Selected in the VR Buffet at 3 Months (time frame: Baseline and 3 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2025; AzTrials last refreshed its copy on 6 Nov 2026.